Proactiveinvestors Australia Cellmid Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Cellmid Ltd RSS feed en Sat, 20 Jul 2019 05:14:54 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Cellmid's Japanese shopping channel sale sets revenue record of $1.14 million ]]> https://www.proactiveinvestors.com.au/companies/news/223328/cellmid-s-japanese-shopping-channel-sale-sets-revenue-record-of-114-million-223328.html Cellmid Ltd (ASX:CDY) has set another sales record after its second sales event this financial year on Japanese television shopping channel QVC delivered revenue of $1.14 million.

This is up from $1.1 million at a similar sales event in December 2018.

These highest ever retail sales of Cellmid’s Jo-Ju® branded hair products have confirmed the brand as one of the best performers of the QVC channel.

Shares up 32%

Investors responded positively with shares up to 27 cents intra-day, a 32% increase on yesterday's close.

The company is undertaking an audit with preliminary analysis of results indicating that sales for the fourth quarter of FY19 are also at a record high of $2.45 million – the highest ever quarterly result for the company.

This is compared to the 2018 quarter four total of $1.34 million.

 

Cellmid chief executive officer Maria Halasz said: “Our recent investment in expanding our senior leadership team and building our marketing capabilities is now translating through to increased sales and new distribution partnerships.

“We enter the 2020 financial year with positive operational momentum in sales growth and e-commerce expansion across Australia, the US and Japan.”

READ: Cellmid évolis professional product range to be sold in Europe

Cellmid is now preparing to launch its new e-commerce platform for its premium product range, évolis Professional, in Japan later this month.

The company has seen a ramp-up in its online performance since the launch of the new évolis website in Australia and the US in March 2019 and is confident that this success can be replicated in Japan in 2020.

READ: Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

Cellmid recently appointed Bart Wuurman as chief executive officer of its wholly-owned subsidiary Lyramid with the aim of unlocking shareholder value by separating the consumer health and biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

Wuurman has successfully executed biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale.

]]>
Thu, 04 Jul 2019 16:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223328/cellmid-s-japanese-shopping-channel-sale-sets-revenue-record-of-114-million-223328.html
<![CDATA[News - Cellmid MD and CEO demonstrates confidence through further on-market share purchase ]]> https://www.proactiveinvestors.com.au/companies/news/221824/cellmid-md-and-ceo-demonstrates-confidence-through-further-on-market-share-purchase-221824.html Cellmid Ltd managing director and CEO Maria Halasz has purchased shares on-market in a further show of confidence in the company’s life sciences strategy.

On May 31 Halasz purchased a further 12,000 shares in the company in an on-market trade and now holds almost 2.2 million shares in direct and indirect interests.

READ: Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase

This follows the purchase of 39,000 shares in early May.

Cellmid is an Australian life sciences company with a consumer health business and biotechnology assets in development, which the company is intending to spin out into two entities.

The former includes the évolis hair care products for which the company is expanding distribution on a global basis.

READ: Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

Cellmid recently appointed Bart Wuurman, an accomplished biotech chief executive, as CEO of its wholly-owned subsidiary Lyramid.

Wuurman has more than 30 years’ experience in innovative drug development, biotech financing, business development and licensing.

He has extensive experience in working with R&D based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases.

This appointment is in line with Cellmid’s strategy to unlock shareholder value by separating the consumer health and the biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

]]>
Tue, 11 Jun 2019 08:53:00 +1000 https://www.proactiveinvestors.com.au/companies/news/221824/cellmid-md-and-ceo-demonstrates-confidence-through-further-on-market-share-purchase-221824.html
<![CDATA[News - Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets ]]> https://www.proactiveinvestors.com.au/companies/news/220999/cellmid-appoints-new-lyramid-ceo-to-drive-clinical-development-of-midkine-assets-220999.html Cellmid Ltd (ASX:CDY) has appointed Bart Wuurman as chief executive officer of its wholly owned subsidiary Lyramid, effective June 1, 2019.

Wuurman is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing.

He has extensive experience in working with R&D based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases.

Separating consumer health and biotech businesses

The appointment of Wuurman is in line with Cellmid’s strategy to unlock shareholder value by separating the consumer health and the biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

 

Wuurman has previously executed successful biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale.

At AM-Pharma, as CEO, he was instrumental in securing a €29 million funding round and a $600 million option deal with Pfizer.

READ: Cellmid’s évolis Professional product range to be sold in Europe

Cellmid CEO Maria Halasz said: “We welcome Bart to the Cellmid leadership team and are very excited to work with him on the midkine portfolio.

“He has a track record of leading successful commercial deals in biotech and we see many opportunities for value creation in taking our midkine assets to the next level of clinical development.”

]]>
Tue, 28 May 2019 12:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220999/cellmid-appoints-new-lyramid-ceo-to-drive-clinical-development-of-midkine-assets-220999.html
<![CDATA[Media files - Cellmid is a well funded life sciences company that see a path to profitability ]]> https://www.proactiveinvestors.com.au/companies/stocktube/13366/cellmid-is-a-well-funded-life-sciences-company-that-see-a-path-to-profitability-13366.html Wed, 15 May 2019 10:20:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/13366/cellmid-is-a-well-funded-life-sciences-company-that-see-a-path-to-profitability-13366.html <![CDATA[News - Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase ]]> https://www.proactiveinvestors.com.au/companies/news/219712/cellmid-managing-director-and-ceo-lifts-holding-in-life-sciences-company-with-on-market-purchase-219712.html Cellmid Limited (ASX:CDY) director Maria Halasz has demonstrated her confidence in the company with the purchase of 39,000 indirect shares at 21 cents a share in on-market trades.

The managing director and chief executive officer increased her holding to 1,585,938 fully paid ordinary shares.

READ: Cellmid’s évolis Professional product range to be sold in Europe

Last month the company registered its évolis Professional anti-ageing hair care products for sale in the European Union and the UK.

This represented the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe.

Cellmid also established a partnership with one of the largest cosmetics retailers in Europe and expects e-commerce sales on the partner’s platform will begin in the first half of the 2020 financial year.

READ: Cellmid alopecia patent granted in Europe for évolis hair therapy

The évolis Professional product range of all 11 SKUS will be sold in EU member states by Cellmid’s cosmetic retail partner.

Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis brand.

]]>
Mon, 06 May 2019 03:09:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219712/cellmid-managing-director-and-ceo-lifts-holding-in-life-sciences-company-with-on-market-purchase-219712.html
<![CDATA[News - Cellmid’s évolis Professional product range to be sold in Europe ]]> https://www.proactiveinvestors.com.au/companies/news/219326/cellmids-volis-professional-product-range-to-be-sold-in-europe-219326.html Cellmid Limited’s (ASX:CDY) évolis® Professional anti-ageing hair care products have been registered for sale in the European Union and the UK representing the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe.

Key treatment and efficacy claims have been retained on the product labels during the review process, which provides for strong market positioning as efficacious products derived from natural plant extracts.

Cellmid has already established a partnership with one of the largest cosmetics retailers in Europe and it is expected that e-commerce sales on the partner’s platform will begin in the first half of financial year 2020.

READ: Cellmid alopecia patent granted in Europe for evolis hair therapy

According to industry reports, 50% of the UK beauty consumers look for products made with natural ingredients and 24% of German consumers choose to buy natural products.

In a discerning market such as the EU, the évolis Professional products - based on plant extracts and with strong clinical evidence - are expected to be well positioned.


 

The évolis Professional product range of all 11 SKUs will be sold in EU member states by Cellmid’s cosmetics retailer partner.

Sales through the e-commerce platform of Cellmid’s retail partner are expected to begin in the first half of next year in the EU, a large, discerning cosmetics market with relatively high disposable income, similar to the US.

Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis® brand.

 

]]>
Tue, 30 Apr 2019 15:43:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219326/cellmids-volis-professional-product-range-to-be-sold-in-europe-219326.html
<![CDATA[News - Cellmid alopecia patent granted in Europe for évolis® hair therapy ]]> https://www.proactiveinvestors.com.au/companies/news/217699/cellmid-alopecia-patent-granted-in-europe-for-volis-hair-therapy-217699.html Cellmid Limited (ASX:CDY) has been advised of the European Patent Office’s intention to grant a patent to protect technologies included in the évolis® hair therapy formulations.

This patent titled ‘Method of treatment of Alopecia with Monoterpenoids’ provides protection in key European territories for hair therapy formulations comprising monoterpenoids.

This class of small molecules is originally derived from botanical extracts.

“Key milestone” for évolis®

Cellmid CEO Maria Halasz said: “The upcoming granting of this patent represents a key milestone for the company’s évolis® products and adds further commercial value to the brand beyond the current sales.”

Imminent granting of this patent comes at a key time in the expansion of the company’s distribution in line with its growth strategy.

It is expected to strengthen ongoing negotiations with potential retail and distribution partners in Europe and other jurisdictions.

READ: Cellmid demonstrates strong operational performance with revenue up to $3.6 million in first half FY19

The method covered by the patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein fibroblast growth factor 5 (FGF5).

Inhibitors of FGF5

Detailed scientific studies have shown that FGF5 activity in hair follicles is associated with disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by follicle rest and hair loss.

Rigorous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Japan showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase.

READ: Cellmid has significant new findings on midkine published in leading medical journal

Halasz said granting of this patent in Europe was an important step for this patent family and was a promising sign for successful grant in other countries such as US, Japan and China.

Cellmid CEO Maria Halasz.

In these countries where significant additional markets for the company’s hair care products exist, the same patent is under examination.

Reduction of hair loss

Topical application of formulations containing key botanical extracts and FGF5-inhibiting monoterpenoids is central to Advangen’s évolis® products against hair loss.

The évolis® products containing monoterpenoid compounds have been shown to reduce hair loss and increase the number of actively growing follicles in a blinded, placebo-controlled clinical study.

These results were published in the journal Clinical, Cosmetic, and Investigational Dermatology (2017) 10: 71-85.

The monoterpenoids-alopecia patents are held by Cellmid’s wholly-owned subsidiary, Advangen Limited.

]]>
Tue, 02 Apr 2019 11:44:00 +1100 https://www.proactiveinvestors.com.au/companies/news/217699/cellmid-alopecia-patent-granted-in-europe-for-volis-hair-therapy-217699.html
<![CDATA[Media files - Cellmid 'on track for record revenues' in FY19, targeting profitability in FY20 ]]> https://www.proactiveinvestors.com.au/companies/stocktube/12319/cellmid--on-track-for-record-revenues--in-fy19-targeting-profitability-in-fy20-12319.html Fri, 22 Feb 2019 09:24:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/12319/cellmid--on-track-for-record-revenues--in-fy19-targeting-profitability-in-fy20-12319.html <![CDATA[News - Cellmid demonstrates strong operational performance with revenue up to $3.6 million in first half FY19 ]]> https://www.proactiveinvestors.com.au/companies/news/215010/cellmid-demonstrates-strong-operational-performance-with-revenue-up-to-36-million-in-first-half-fy19-215010.html Cellmid Limited (ASX:CDY) has demonstrated a strong operational performance in both the consumer health and biotechnology divisions of the company for the first half of the 2019 financial year.

Revenue of $3.6 million was up 12% on the previous corresponding period (PCP), reflecting a diversified mix including sales from Japan and the company’s net assets increased by 89% on PCP to $8.2 million.

Significant one-off costs such as the payment of the Ikon award and the Platinum road facility took place with the balance sheet improving significantly after a $9.6 million capital raising.

“Enter 2019 in a strong position”

Cellmid chief executive officer Maria Halasz said: “We enter 2019 in a strong position to drive revenue growth across different markets and different channels.

“Our 'path to profitability 2020' strategy lays out the foundations for maximising shareholder value from both our consumer health and biotech assets.”

With deliberate focus on pursuing only those sales channels that are profitable, the company’s most mature geographical segment, Japan, has been delivering growing after-tax profits since financial year 2016.

The same discipline has been applied in Australia with benefits from this program expected to improve profitability from the second half of the 2019 financial year, as new products and more profitable distribution channels are progressively activated.

READ: Cellmid has significant new findings on midkine published in leading medical journal

In the coming months Cellmid will focus on increasing high margin sales through an aggressive e-commerce campaign in the US and Australia, expanding premium retail distribution in the US and building on the QVC television shopping channel in Japan and China.

In the medium term the company’s distribution agreement with its Chinese partner Fukangren Pharma is expected to produce transformational growth once regulatory approval for the Australian manufactured Evolis pharmacy range is received.

READ: Cellmid becomes profitable in December after achieving record quarterly sales

Concurrently and while maintaining a low-cost collaboration model, the company’s midkine asset portfolio will be packaged for clinical development and partnership.

Cellmid chairman David King said: “With both asset portfolios well on their way to achieving their targets, the board is pleased to report a clean and strong balance sheet and to provide further details on its two-year strategic plan.”

 

 

Earlier this month the company revealed that the prestigious Journal of Experimental Medicine had published a significant study showing for the first time that midkine, for which the company holds intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis.

The company’s midkine antibodies prevent cardiac muscle damage due to rampant inflammation, thereby reducing fibrosis and preserving cardiac function. 

]]>
Thu, 21 Feb 2019 00:16:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215010/cellmid-demonstrates-strong-operational-performance-with-revenue-up-to-36-million-in-first-half-fy19-215010.html
<![CDATA[News - Cellmid has significant new findings on midkine published in leading medical journal ]]> https://www.proactiveinvestors.com.au/companies/news/214135/cellmid-has-significant-new-findings-on-midkine-published-in-leading-medical-journal-214135.html Cellmid Ltd (ASX:CDY) has revealed that the prestigious Journal of Experimental Medicine has published a significant study showing for the first time that midkine, around which the company holds extensive intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis.

Cellmid’s midkine antibodies prevent cardiac muscle damage due to rampant inflammation, thereby reducing fibrosis and preserving cardiac function.

READ: Cellmid becomes profitable in December after achieving record quarterly sales

The paper by Cellmid collaborators Dr Ludwig Weckbach and Professor Barbara Walzog describes how midkine is key to the inflammatory processes of myocarditis leading to cardiomyopathy and end-stage heart failure.

As the holder of the most significant intellectual property assets around midkine globally, the publication provides Cellmid with exposure to and a strong platform for partnerships.

Important further studies planned

The findings of midkine’s role in autoimmune myocarditis may be relevant to the dangerous side effects of new blockbuster cancer drugs that boost the immune system to combat tumours.

By taking the breaks off the immune system, checkpoint inhibitors often cause immune related adverse events that can develop rapidly and, in the case of autoimmune myocarditis, are fatal in about one to four percent of all patients treated with checkpoint inhibitors.

Cellmid head of R&D Dr Graham Robertson said: “The potential of Cellmid’s midkine antibodies to alleviate the heart failure experienced by cancer patients may lead to deploying our midkine assets as an adjunct therapy in oncology to work alongside immuno-oncology drugs.”

READ: Cellmid builds IP for midkine portfolio with new patents

The latest findings and planned future studies support the therapeutic application of Cellmid’s midkine antibodies in the treatment of myocarditis, including myocarditis resulting from injury to the myocardium by toxins, therapeutic agents and other drugs, infectious agents and other autoimmune diseases/conditions.

]]>
Thu, 07 Feb 2019 13:29:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214135/cellmid-has-significant-new-findings-on-midkine-published-in-leading-medical-journal-214135.html
<![CDATA[News - Cellmid becomes profitable in December after achieving record quarterly sales ]]> https://www.proactiveinvestors.com.au/companies/news/213109/cellmid-becomes-profitable-in-december-after-achieving-record-quarterly-sales-213109.html Cellmid Limited (ASX:CDY) has posted record sales for the second quarter of financial year 2019, earning $2.2 million or an 8% increase on the same period last year.

The company became profitable for the month of December 2018 with $278,000 net profit after tax received.

Sales growth continued across all of Cellmid’s divisions, with the USA recording the highest growth rate while Japan remains the largest contributor in terms of sales revenue.

Cellmid continued preparation of its orphan drug application during the quarter and expects to complete a filing during the March quarter.

 

Cellmid chief executive officer Maria Halasz said: “Our cash position will be further boosted in quarter three financial year 2019 as our record accounts receivable arrives.

“In addition, we have repaid all of our major debt and we are now in a strong financial position to fulfil growth expectations in current and new channels.”

READ: Cellmid driving towards profitability with anti-ageing product range

The company’s cash balance at the end of the December quarter was $5.4 million, down from $9.26 million at the end of the previous quarter.

The current receivables balance is over $1.5 million which Cellmid expects to contribute to strong cash receipts in the coming March quarter.

Significant cash outflows during the quarter included the repayments of the remaining Platinum Road loan facility with interest.

READ: Cellmid expecting record sales in December quarter, shares up 15%

Part of the company’s growth strategy has been securing the supply chain for évolis activator bottles and other packaging products.

During the quarter, Cellmid placed major orders for supplies of évolis product components to rapidly fulfil orders in the growing US and Japanese distribution.

évolis is a clinically-validated portfolio of anti-ageing hair treatments

 

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

In November last year the company’s Lyramid patent application, entitled ‘Antibody recognizing N-domain of midkine’, was granted by the US Patent Office.

Cellmid has also received a notification of intention to grant from the European Patent Office for the corresponding Lyramid patent in key European territories.

The newly-granted midkine antibody patents and allied patent families underpin Cellmid’s intellectual property position over the use of therapeutic midkine antibodies.

This includes their use in treating diseases such as cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune disease.

READ: Cellmid builds IP for midkine portfolio with new patents

Cellmid is an Australian life sciences company with lead programs in multiple disease indications.

The company develops and markets novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5 globally.

]]>
Tue, 22 Jan 2019 19:23:00 +1100 https://www.proactiveinvestors.com.au/companies/news/213109/cellmid-becomes-profitable-in-december-after-achieving-record-quarterly-sales-213109.html
<![CDATA[News - Cellmid expecting record sales in December quarter, shares up 15% ]]> https://www.proactiveinvestors.com.au/companies/news/211010/cellmid-expecting-record-sales-in-december-quarter-shares-up-15-211010.html Cellmid Ltd (ASX:CDY) expects its sales revenue to reach a record $2.2 million for the December quarter.

This is supported by a recent sales event on its Japanese television shopping channel that delivered sales revenue of $1.1 million.

Cellmid’s Jo-Ju® branded Japanese hair growth products have proven to be one of the most successful cosmetics ever on the Japanese television shopping channel.

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

Cellmid’s CEO Maria Halasz said: “With around 50,000 QVC customers, a large number of them regulars, we have a strong following for our Jo-Ju® products in Japan.

“We intend to build on this to maximise the potential for our recently launched évolis® products in multiple sales channels in Japan.”

Switch to plastic bottles to increase profit margin

Cellmid recently changed packaging for its Jo-Ju® lotions from glass to plastic bottles.

As a result, net profit margins are expected to increase by around 10%, whilst manufacturing time reduced from seven months to as little as three months.

This, in turn, will allow better utilisation of working capital.

Smoothing out sales going forward

Major sales events, such as those on Japenese television channel QVC currently represent material components of sales revenue, resulting in significant fluctuations in quarterly sales.

Cellmid has been working towards setting up distribution in channels that deliver more even monthly sales.

Furthermore, the company has been actively building distribution in other channels and geographies to reduce reliance on sales from TV shopping.

]]>
Wed, 12 Dec 2018 12:04:00 +1100 https://www.proactiveinvestors.com.au/companies/news/211010/cellmid-expecting-record-sales-in-december-quarter-shares-up-15-211010.html
<![CDATA[News - Cellmid partners with NZ pharmacies to distribute anti-ageing products ]]> https://www.proactiveinvestors.com.au/companies/news/209410/cellmid-partners-with-nz-pharmacies-to-distribute-anti-ageing-products-209410.html Cellmid Limited (ASX:CDY) has appointed Pharmaceutical Services Ltd (PSL) as the exclusive distributor of its anti-ageing consumer products in New Zealand.

PSL will use its existing facilities and skilled field force to provide warehousing, fulfilment, distribution and sales support to increase market penetration for Cellmid’s évolis® and Fillerina® brands.

READ: Cellmid builds IP for midkine portfolio with new patents

During the first 12 months of the agreement, the companies will collaborate to increase distribution and sales and will then develop minimum sales targets for after the first year.

The agreement does not have a fixed term and will remain exclusive subject to PSL’s performance from the second year onwards.

Cellmid will support PSL with full marketing training to roll out distribution in a similar way to retailers in the US and pharmacies in Australia.

This training will include experiential marketing strategies such as the évoliscope® and in-store product sampling.

READ: Cellmid launches évolis® Professional products in 17 store locations across the US

PSL is owned by the Pharmacy Guild of New Zealand and supplies most of its 1,000-pharmacy membership.

There are over 3,500 practising pharmacies in New Zealand with over 1,000 community pharmacies.

Most pharmacies are still owned by independent pharmacists, but according to Cellmid corporatisation has been on legislators’ radar since 2016.

Corporatisation will bring competition and independent pharmacies with unique offerings, such as Cellmid’s anti-ageing hair and skin products, will have an opportunity to remain leaders in the market.

 

Cellmid is an Australian life sciences company with lead programs in multiple disease indications.

The company develops and markets novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5 globally.

]]>
Sun, 18 Nov 2018 20:11:00 +1100 https://www.proactiveinvestors.com.au/companies/news/209410/cellmid-partners-with-nz-pharmacies-to-distribute-anti-ageing-products-209410.html
<![CDATA[News - Cellmid builds IP for midkine portfolio with new patents ]]> https://www.proactiveinvestors.com.au/companies/news/208680/cellmid-builds-ip-for-midkine-portfolio-with-new-patents-208680.html Cellmid Ltd (ASX:CDY) has strengthened and secured the intellectual property (IP) in its midkine antibodies portfolio after being granted a US patent and advancing a European patent.

The US Patent Office granted the patent application entitled "Antibody recognizing N-domain of midkine".

In addition, Cellmid received a ‘Notification of Intention to Grant’ from the European Patent Office for the corresponding patent in key European territories.

READ: Cellmid launches évolis® Professional products in 17 store locations across the US

The newly granted midkine antibody patents and allied patent families underpin the company’s dominant IP position over the use of therapeutic midkine antibodies for the treatment of diseases.

These diseases arise from cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune diseases.

Midkine is an important early marker for diagnosing diseases

Midkine is a growth factor that is highly expressed during embryonic development.

It modulates many important biological interactions such as cell growth that are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing.

Midkine is barely detectable in healthy adults midkine expression is often evident very early in disease onset, even before any apparent physical symptoms.

Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases.

Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

]]>
Wed, 07 Nov 2018 11:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/208680/cellmid-builds-ip-for-midkine-portfolio-with-new-patents-208680.html
<![CDATA[News - Cellmid launches évolis® Professional products in 17 store locations across the US ]]> https://www.proactiveinvestors.com.au/companies/news/208278/cellmid-launches-volis-professional-products-in-17-store-locations-across-the-us-208278.html Cellmid Ltd (ASX:CDY) has successfully completed the initial 17-store launch in the US for its anti-aging hair care range, évolis® Professional.

As a result of the strong response during these launch events, all three retail partners (Bloomingdales, Neiman Marcus and Soft Surroundings) have advised on additional store locations for the products.

READ: Cellmid set to launch its anti-aging hair care range in major stores across the U.S.

Bloomingdales will stock évolis® Professional in eight additional stores from January 2019, taking the total store presence to nine flagship locations, representing about 2.5% of the total store numbers within the Macy’s Group (NYSE:M).

Cellmid will be given five additional Neiman Marcus store placements from March 2019 and a further 10 store placements from September 2019, taking the total number of Neiman Marcus doors to 20 by late 2019, representing around 30% of the total number of stores within the group.

Following the strong in-store performance, a further 10 Soft Surroundings stores will range the évolis® Professional products from early 2019, taking the total number of doors to 21, representing about 20% of the total number of stores within the group.

READ: Cellmid driving towards profitability with anti-ageing product range

With a substantial increase in store locations across the US, Cellmid is now focused on implementing a cost-effective experiential marketing solution.

The company has signed an agreement with a US retail specialist providing local brand ambassadors on a contract basis from the end of November 2018.

Cellmid CEO Maria Halasz said: “Our US team, led by Colour Collective’s managing director Kerry Yates, has done an exceptional job during the launch events

“The results confirm our differentiated launch strategy and give us confidence to continue to scale into this lucrative distribution channel using a professional, cost effective, local retail team”

Early repayment of R&D loan

Cellmid has repaid the remaining $1 million of the $2 million R&D loan facility provided to it by Platinum Road in February 2017.

By repaying the entire $2 million of the loan before due date, Cellmid has saved a total of $90,000 in interest.

With the recent $10 million fundraising, $9 million in a private placement, a further $1 million via a share purchase plan, and the R&D tax credit received of $808,000, Cellmid is well funded to maximise the growth potential of its business and continue on the path of improved financial performance.

]]>
Thu, 01 Nov 2018 12:39:00 +1100 https://www.proactiveinvestors.com.au/companies/news/208278/cellmid-launches-volis-professional-products-in-17-store-locations-across-the-us-208278.html
<![CDATA[News - Cellmid banks research and development tax incentive ]]> https://www.proactiveinvestors.com.au/companies/news/208077/cellmid-banks-research-and-development-tax-incentive-208077.html Cellmid Limited (ASX:CDY) has received $808,000 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2018 financial year.

The tax credit relates to research and development expenditure incurred by Cellmid in relation to its midkine (MK) and FGF5 inhibitor programs.

Cellmid’s évolis® hair growth product range was developed using FGF5 related intellectual property.

The company aims to follow in the footsteps of FGF5 by commercialising its MK portfolio through various deals and partnerships.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products for hair, face and wellbeing.

Thanking @goodthingsarewaiting for her review of our #promoteprotector and #whitemask Check it -> https://t.co/bNmsS16U2j #reviews #feedback #healthyhair pic.twitter.com/0gQtSZndZa

— évolis (@evolis_products) September 24, 2018

The segment generated $5.64 million in revenue in FY2018 and as Cellmid expands its product range and selling markets, it is closing in on profitability.

]]>
Tue, 30 Oct 2018 15:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/208077/cellmid-banks-research-and-development-tax-incentive-208077.html
<![CDATA[News - Cellmid director shows faith in life sciences company through on-market trades ]]> https://www.proactiveinvestors.com.au/companies/news/205598/cellmid-director-shows-faith-in-life-sciences-company-through-on-market-trades-205598.html Cellmid Limited (ASX:CDY) non-executive director Bruce Gordon continues to demonstrate his confidence in the life sciences company through on-market share purchases.

Gordon has acquired a further 8,684 shares valued at almost $3,300 and now holds 110,000 shares in an indirect interest.

Last week’s acquisition follows a recent purchase of more than 26,000 shares valued at $10,000.

READ: Cellmid gains new substantial shareholder as director increases his interest to 6.4%

Other company directors have also been acquiring shares recently in a variety of ways, including on-market trades and participation in the recent share placement and share purchase plan.
US-based non-executive director Dennis Eck is a substantial shareholder with a 6.4% interest after acquiring a further batch of shares valued at $1 million.

Managing director and CEO Maria Halasz acquired shares valued at $100,000 while non-executive director Dr Martin Cross has made purchases valued at $50,400.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. 

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

]]>
Tue, 25 Sep 2018 14:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205598/cellmid-director-shows-faith-in-life-sciences-company-through-on-market-trades-205598.html
<![CDATA[News - Cellmid driving towards profitability with anti-ageing product range ]]> https://www.proactiveinvestors.com.au/companies/news/204971/cellmid-driving-towards-profitability-with-anti-ageing-product-range-204971.html Cellmid Ltd (ASX:CDY) has three wholly owned subsidiaries operating in two distinct business segments – (1) consumer health; and (2) pre-clinical therapeutic assets.

The consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products for hair, face and wellbeing.

The segment generated $5.64 million in revenue in FY2018 and as Cellmid expands its product range and selling markets, it is closing in on profitability.

Recently in December 2018, Cellmid revealed that it expected its sales revenue to reach a record $2.2 million for the December quarter.

READ: Cellmid expecting record sales in December quarter, shares up 15%

Cellmid’s product range features évolis® and Fillerina®.

évolis® is a clinically validated, TGA listed portfolio of hair care treatment products specifically formulated as an anti-ageing hair solution.

The product range is sold across Australia, New Zealand, Japan, China and the US.

Fillerina® is the first non-injectable transdermal filler that has been clinically validated to reduce wrinkles and increase facial volume.

In April 2018, Cellmid entered into a distribution agreement for Fillerina to be sold in Australia and New Zealand through Labo International, a European cosmetics company.

Recent sales driven by Japan’s Jo-Ju® hair growth products

The expectations for a strong December sales quarter were supported by a sales event on its Japanese television shopping channel that delivered sales revenue of $1.1 million.

Cellmid’s Jo-Ju® branded Japanese hair growth products have proven to be one of the most successful cosmetics ever on the Japanese television shopping channel QVC.

Cellmid’s CEO Maria Halasz said: “With around 50,000 QVC customers, a large number of them regulars, we have a strong following for our Jo-Ju® products in Japan.

“We intend to build on this to maximise the potential for our recently launched évolis® products in multiple sales channels in Japan.”

READ: Cellmid launches évolis® Professional products in 17 store locations across the US

In November 2018, Cellmid successfully completed the initial 17-store launch in the US for its anti-aging hair care range, évolis® Professional.

With a substantial increase in store locations across the US, Cellmid is focused on implementing a cost-effective experiential marketing solution.

The company signed an agreement with a US retail specialist providing local brand ambassadors on a contract basis from the end of November 2018.

Notably, as a result of the strong response during these launch events, all three retail partners (Bloomingdales, Neiman Marcus and Soft Surroundings) advised Cellmid on additional store locations for the products.

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

Furthermore, during November 2018, Cellmid also appointed Pharmaceutical Services Ltd (PSL) as the exclusive distributor of its anti-ageing consumer products in New Zealand.

Monetising its pre-clinical therapeutic assets

Cellmid’s second business segment, pre-clinical therapeutic assets refers to its midkine (MK) portfolio.

The évolis® hair growth product range was developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio through various deals and partnerships.

Lyramid Limited and Kinera Limited are Cellmid’s wholly-owned subsidiaries that own and develop MK related research and development programs.

READ: Cellmid builds IP for midkine portfolio with new patents

Kinera holds MK protein for the treatment of heart failure, chronic heart conditions and ischemic diseases.

Lyramid holds MK antibodies for the treatment of myocarditis, cancer, fibrosis, chronic kidney disease and associated conditions

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

In September 2018, Cellmid received positive efficacy results from its lead anti-midkine antibody, CAB102, against focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

Notably, the humanised antibody reduced the area of kidney injury 3-fold compared to vehicle-treated control mice with FSGS, while renal function was improved.

This was a critical step in progressing Cellmid’s antibody assets towards clinical trials in kidney patients.

]]>
Mon, 17 Sep 2018 07:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204971/cellmid-driving-towards-profitability-with-anti-ageing-product-range-204971.html
<![CDATA[News - Cellmid gains new substantial shareholder as director increases his interest to 6.4% ]]> https://www.proactiveinvestors.com.au/companies/news/204899/cellmid-gains-new-substantial-shareholder-as-director-increases-his-interest-to-64-204899.html Cellmid Ltd (ASX:CDY) has a new substantial shareholder with US-based non-executive director Dennis Eck now holding a 6.4% interest in the life sciences company.

Eck has this month acquired more than 2.63 million shares valued at $1 million, bringing the total number held to more than 5.331 million.

This acquisition follows one last December in which he acquired 2.7 million shares for total value of $1.026 million.

 

Eck’s confidence in the company is shared by other directors who have made recent purchases in a variety of ways.

These include on-market trades and participation in the recent share placement and share purchase plan (SPP).

Managing director and CEO Maria Halasz acquired 263,157 shares valued at for $100,000 while non-executive directors Bruce Gordon and Dr Martin Cross have made purchases valued at $10,000 and $50,400 respectively.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.  

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

]]>
Fri, 14 Sep 2018 16:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204899/cellmid-gains-new-substantial-shareholder-as-director-increases-his-interest-to-64-204899.html
<![CDATA[News - Cellmid board members hoover up company stock ]]> https://www.proactiveinvestors.com.au/companies/news/204783/cellmid-board-members-hoover-up-company-stock-204783.html Cellmid Ltd (ASX:CDY) has had four of its board members purchase company stock recently with one member buying $1 million worth of shares.

The share purchases were made in a variety of ways including on-market trades and participation in the recent share placement and share purchase plan (SPP).

The board members that increased their holdings were managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck.

Eck acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

 

]]>
Thu, 13 Sep 2018 12:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204783/cellmid-board-members-hoover-up-company-stock-204783.html
<![CDATA[News - Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease ]]> https://www.proactiveinvestors.com.au/companies/news/204687/cellmids-study-confirms-effectiveness-of-lead-antibody-against-rare-chronic-kidney-disease-204687.html Cellmid Limited (ASX:CDY) has received positive efficacy results from its lead anti-midkine antibody, CAB102, against focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

Notably, the humanised antibody reduced the area of kidney injury 3-fold compared to vehicle-treated control mice with FSGS, while renal function was improved.

Milestone in progressing antibody assets towards clinical trials

The study performed at the Westmead Institute confirmed previous findings, that blocking midkine alleviates damage to the kidney and prevents ensuing defects in renal function.

Furthermore, it demonstrated that a humanised antibody targeting midkine, CAB102, is equally as effective as its murine precursor.

This is a critical step in progressing Cellmid’s antibody assets towards clinical trials in kidney patients.

 

Demonstrating efficacy of the humanised midkine antibody in the rare kidney disorder FSGS enables Cellmid to apply to the US FDA and European EMA for Orphan Drug Designation for CAB102.

The benefits of Orphan Drug status include tax credits for costs of clinical trials, fee waiver and eligibility for seven years of marketing exclusivity.

These incentives would represent a major boost to Cellmid’s clinical development programs.

Cellmid chief executive officer Maria Halasz said: “We are excited that engagement with some of the leading renal clinicians and researchers in the field of chronic kidney disease globally has lead us one step closer to clinical deployment of our anti-midkine assets.”

READ: Cellmid closes share purchase plan after crossing target amount

The company recently closed its share purchase plan (SPP) after receiving applications to the value of $1,025,000 at a price of 38 cents per share.

The SPP was at the same price as Cellmid’s recent share placement to sophisticated and institutional investors for $9 million.

]]>
Wed, 12 Sep 2018 11:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204687/cellmids-study-confirms-effectiveness-of-lead-antibody-against-rare-chronic-kidney-disease-204687.html
<![CDATA[News - Cellmid closes share purchase plan after crossing target amount ]]> https://www.proactiveinvestors.com.au/companies/news/204012/cellmid-closes-share-purchase-plan-after-crossing-target-amount-204012.html Cellmid Limited (ASX:CDY) has closed its share purchase plan (SPP) announced on July 31, 2018 with an offer price of 38 cents.

The company received applications to the value of $1,025,000 for the issuing of 2,697,377 shares, which is $25,000 over the maximum $1 million originally determined by the board.

Cellmid has approved the oversubscription and there will be no scale back of applications.

The SPP was offered at the same price as the share placement to sophisticated and institutional investors for $9 million, also announced on 31 July 2018.

READ: Cellmid raises $9 million for distribution and invites shareholders to invest $1 million

The funds raised under the SPP and the private placement will be used to drive growth in the consumer health business globally, specifically that of the flagship évolis® product range and the exclusive distribution agreement with Fillerina in Australia and New Zealand.

Cellmid chief executive officer Maria Halasz said: “We thank all participating shareholders and new investors for their support in the capital raising as we continue to advance distribution opportunities for our portfolio of high growth anti-aging consumer health products in major global markets”.

 

Cellmid recently commenced the instore launch of its anti-aging hair care range, évolis Professional, on August 31, 2018 in Neiman Marcus and Soft Surroundings stores across the U.S.

The in-store launches are being supported by major public relations and social media campaigns in addition to full-day experiential marketing events hosted by each store.

The theme for each of the 16 events will be built around the use of Cellmid’s proprietary évoliscope™ technology, which allows customers to assess their hair health.

]]>
Mon, 03 Sep 2018 11:13:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204012/cellmid-closes-share-purchase-plan-after-crossing-target-amount-204012.html
<![CDATA[News - Cellmid set to launch its anti-aging hair care range in major stores across the U.S. ]]> https://www.proactiveinvestors.com.au/companies/news/203835/cellmid-set-to-launch-its-anti-aging-hair-care-range-in-major-stores-across-the-us-203835.html Cellmid Limited (ASX:CDY) will commence the instore launch of its anti-aging hair care range, évolis® Professional, on August 31, 2018 in Neiman Marcus and Soft Surroundings stores across the U.S.

As part of the launch, a series of experiential marketing events will be held in flagship Neiman Marcus stores in Hawaii (Ala Moana), California (Fashion Island), Florida (Orlando) and Texas (Northpark and Houston).

Similar events will be held in 11 Soft Surroundings stores, from Arizona to Texas, during the same period.

 

Neiman Marcus, founded in Dallas, Texas in 1907, is one of the oldest and most prestigious department stores in the U.S.

The group operates 42 Neiman Marcus stores across the United States and two Bergdorf Goodman stores in Manhattan.

Soft Surroundings, a women’s apparel, beauty and home décor chain, was founded as a catalogue business in St Louis, Missouri, and opened its first store in 2005.

Soft Surroundings has over 70 stores across the U.S. and is growing.

READ: Cellmid raises $9 million for distribution and invites shareholders to invest $1 million

The in-store launches are being supported by major public relations and social media campaigns in addition to full-day experiential marketing events hosted by each store.

The theme for each of the 16 events will be built around the use of Cellmid’s proprietary évoliscope™ technology, which allows customers to assess their hair health.

Find your next hair hero in #evolis White! https://t.co/2Jf5l6yq4z #justarrived #healthyhair #evolishair #hairinspo #evolis #AntiAging pic.twitter.com/rebJNZjWM8

— évolis (@evolis_products) August 3, 2018

Cellmid chief executive officer Maria Halasz said: “Store presence is expected to increase sales significantly from what has been a very successful online launch of the évolis® Professional products in Neiman Marcus and Soft Surroundings.

“Previous events not only generated high conversion rates, but an opportunity to train store staff and allow them to become product champions.”

]]>
Thu, 30 Aug 2018 11:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/203835/cellmid-set-to-launch-its-anti-aging-hair-care-range-in-major-stores-across-the-us-203835.html
<![CDATA[Media files - Cellmid expanding products, portfolio and markets; and approaching profitablity ]]> https://www.proactiveinvestors.com.au/companies/stocktube/10004/cellmid-expanding-products-portfolio-and-markets-and-approaching-profitablity-10004.html Wed, 01 Aug 2018 16:59:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/10004/cellmid-expanding-products-portfolio-and-markets-and-approaching-profitablity-10004.html <![CDATA[News - Cellmid raises $9 million for distribution and invites shareholders to invest $1 million ]]> https://www.proactiveinvestors.com.au/companies/news/201879/cellmid-raises-9-million-for-distribution-and-invites-shareholders-to-invest-1-million-201879.html Cellmid Limited (ASX:CDY) has raised $9 million from sophisticated and institutional investors and will invite shareholders to participate in a $1 million share placement plan.

The $9 million from high-quality investors is split into two tranches, with one to be approved by shareholders.

 

 

Cellmid said the placement “closed with strong demand from new and existing institutional investors”.

READ: Cellmid lays out major plan for product and distribution expansion

Proceeds will provide working capital to drive distribution of Cellmid’s products and grow its health business, pushing out its flagship évolis product range, and facilitating distribution in Australia, New Zealand and new global markets.

Sydney-based Cellmid hopes to increase its proceeds from an exclusive distribution agreement with Fillerina for the two Southern Hemisphere countries.

READ: Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

Cellmid chairman Dr David King said: “We are delighted to secure funding for the expansion of our consumer health business at this critical stage.

“The funding will allow us to turbo charge our growth plans and take the company closer to profitability.”

It comes at a fortuitous time as distribution channels have been set up in major global markets such as China and the US.

READ: Cellmid set to launch its évolis hair care products in the lucrative Chinese market

The Blue Ocean Equities Pty Ltd-led 23.7 million placement was priced at 38 cents a share, which was a 17.8% discount to Cellmid’s 30-day VWAP on its last trading day of July 26.

The tranche that investors will be asked to approve at an annual meeting pencilled in for September 7 will be a 12.5% placement to directors: 11.1% to the Dennis Eck family, 0.3% to Martin Cross and 1.1% to managing director and CEO Maria Halasz.

That tranche makes up more than 19 million shares and about $7.3 million of the capital raising while the remaining unconditional placement will bring in about $1.7 million.

The unconditionally approved shares will be settled on Friday and allotted next Monday.

If the director component of the share-raising is approved, the shares are expected to be settled on August 11 and allotted the next day.

READ: Cellmid secures partnership with Bloomingdales to sell évolis

Shareholders will be able to participate in the offer at the same buy-in price for a $15,000 maximum increase to their investment.

The investors must have been on the share register at 7pm Australian Eastern Standard Time yesterday and be registered to an Australian or New Zealand address.

]]>
Tue, 31 Jul 2018 00:11:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201879/cellmid-raises-9-million-for-distribution-and-invites-shareholders-to-invest-1-million-201879.html
<![CDATA[News - Cellmid granted ASX trading halt prior to capital raising news ]]> https://www.proactiveinvestors.com.au/companies/news/201693/cellmid-granted-asx-trading-halt-prior-to-capital-raising-news-201693.html Cellmid Limited (ASX:CDY) has been granted an ASX trading halt before releasing details of a proposed capital raising.

The securities will remain in a trading halt until the earlier of the start of normal trading on Tuesday, 31 July, or when the announcement is released to the market.

Cellmid was 46 cents at the close of trade on Thursday.

READ: Cellmid lays out major plan for product and distribution expansion

The life sciences company plans to expand distribution of products in the US and Japan as well as increase its product range in Australia.

This is expected to result in an increase in revenue in the 2019 financial year.

Cellmid’s évolis products are specifically formulated anti-ageing hair solutions, which include shampoos, conditioners, sprays and activators.

US in-store placement

For the first time évolis Professional products will be sold permanently in Neiman Marcus and Bloomingdales stores from September 2018.

The first Neiman Marcus stores designated for the full range of the évolis Professional products are Ala Moana (Hawaii), Fashion Island (California), Orlando (Florida), Northpark (Texas) and Houston (Texas).

These are flagship stores with well-trained sales associates and loyal customers.

Bloomingdales’ flagship store in New York will also carry the full évolis Professional range with other stores expected to come online in the next six months.

Launch in Japan

Cellmid aims to launch the évolis branded FGF5 inhibitor anti-ageing hair products in Japan.

The évolis Professional range was scheduled to be launched this month while the évolis Pharmacy will be launched in October.

This is the first time that the Australian manufactured products will be exported to Japan and it follows a period of extensive product testing on Japanese customers assessing both beauty and therapeutic applications.

The évolis Professional range will be progressively introduced to suitable Australian pharmacies from this month.

This will increase the number of products sold from four to 15 within the brand in these pharmacies.

]]>
Fri, 27 Jul 2018 09:22:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201693/cellmid-granted-asx-trading-halt-prior-to-capital-raising-news-201693.html
<![CDATA[News - Cellmid lays out major plan for product and distribution expansion ]]> https://www.proactiveinvestors.com.au/companies/news/200526/cellmid-lays-out-major-plan-for-product-and-distribution-expansion-200526.html Cellmid Limited (ASX:CDY) is anticipating a substantial increase in revenue in FY2019 following the planned expansion of distribution in the US and Japan and the increase in products in Australia.

USA - in-store placement from September 2018

Cellmid’s évolis range of products are specifically formulated anti-aging hair solutions which include shampoos, conditioners, sprays and activators.

For the first time évolis Professional products will be sold permanently in Neiman Marcus and Bloomingdales stores from September 2018.

The first Neiman Marcus stores designated for the full range of the évolis Professional products are Ala Moana (Hawaii), Fashion Island (California), Orlando (Florida), Northpark (Texas) and Houston (Texas).

These are flagship stores with well-trained sales associates and loyal customers.

READ: Cellmid secures partnership with Bloomingdales to sell évolis

Bloomingdales’ flagship store in New York will also carry the full évolis Professional range with other stores expected to come online in the next six months.

Japan - evolis launch in salons and pharmacies

The évolis branded FGF5 inhibitor anti-aging hair products will be launched in Japan in July 2018 (évolis Professional) and October 2018 (évolis pharmacy).

This is the first time that the Australian manufactured products will be exported to Japan and it follows a period of extensive product testing on Japanese customers assessing both beauty and therapeutic applications.

The sales channels for évolis Professional will be e-commerce and hair salons, while the évolis pharmacy range will be sold through independent chemists.

Australia and USA - new product launches

The évolis Professional range will be progressively introduced to suitable Australian pharmacies from July 2018.

This will increase the number of products sold from 4 to 15 within the brand in these pharmacies.

The évolis WHITE mask was launched in Australia in July 2018 and will be sold through pharmacies and salons in addition to Cellmid’s e-commerce platform.

Fillerina, the anti-aging transdermal filler product range with 11 variants, will be launched in Australian pharmacies progressively from September 2018.

Initial store locations have been secured with 70% of the first order already allocated to participating pharmacies.

The évolis Professional REVERSE Dry Shampoo is expected to be launched in Australia and USA in October 2018.

This product will be sold through all channels including premium retailers in the USA and pharmacies in Australia.

The évolis PROMOTE Protect spray will also be launched in beta test mode this month via e-commerce.

]]>
Wed, 11 Jul 2018 11:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200526/cellmid-lays-out-major-plan-for-product-and-distribution-expansion-200526.html
<![CDATA[News - Cellmid set to launch its évolis hair care products in the lucrative Chinese market ]]> https://www.proactiveinvestors.com.au/companies/news/196202/cellmid-set-to-launch-its-volis-hair-care-products-in-the-lucrative-chinese-market-196202.html Cellmid Limited’s (ASX:CDY) wholly owned subsidiary Advangen has entered into an exclusive agreement to distribute its évolis® anti-aging hair care products in the Peoples Republic of China.

The company has signed a five-year agreement with Beijing Fukangren Bio-pharm Tech Co Ltd for the distribution of évolis lotions and shampoos.

The agreement between Advangen and Fukangren has two key stages:

• A 12-month period where, for and on behalf of Advangen, Fukangren will register the évolis lotions as hair loss products with the Chinese regulator, SFDA (State Food & Drug Administrator); and
• An exclusive distribution agreement for the évolis® lotions and shampoos for five years with minimum order requirements for each year.

READ: Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

Shares were up almost 10% intra-day to 56.5 cents.

évolis is being launched in China following extensive market research regarding product demand, fit and pricing against comparable products within the Chinese market.

The first-in-class FGF5 inhibitor technology of évolis with natural active ingredients provides it with a unique marketing proposition and a significant competitive edge.

Adding further differentiation in the Chinese market is the highly desirable “Australian made” and “Japanese made” status of the évolis products.

Fukangren has the potential to make évolis a success in China

Beijing Fukangren, established in 2000, is a rapidly growing pharmaceutical company with over 400 staff, distributing over 300 products including generics and drugs under licence and profit arrangement.

Fukangren also has a specialist regulatory affairs team with a strong track record of successful applications with the Chinese regulator, SFDA.

Cellmid chief executive officer Maria Halasz said: “This agreement is an important step towards bringing évolis to the Chinese people, and we believe Fukangren has the resources, capacity and market know-how to make évolis a success in China.”

Chinese market opportunity

Three recent surveys of university students identified hair loss concerns among younger Chinese citizens, with 60-70% of respondents indicating that they were suffering from hair loss or had hair loss concerns.

Cellmid has a significant potential in China, given the magnitude of the country’s population and the size of its new middle class, estimated at over 100 million households with growing disposable income.

Halasz added: “The Chinese market is a key element of Cellmid’s growth strategy and we expect it will contribute significantly to growing our revenues in the coming years.”

]]>
Wed, 02 May 2018 12:14:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196202/cellmid-set-to-launch-its-volis-hair-care-products-in-the-lucrative-chinese-market-196202.html
<![CDATA[News - Cellmid secures partnership with Bloomingdales to sell évolis® ]]> https://www.proactiveinvestors.com.au/companies/news/195611/cellmid-secures-partnership-with-bloomingdales-to-sell-volis-195611.html Cellmid Ltd (ASX:CDY) has secured a new premium retail partnership with leading US retailer, Bloomingdales, for its évolis® Professional product range.

The in-store launch is planned for the upcoming September quarter at Bloomingdales, one of the oldest and most prestigious department stores in the US.

Bloomingdales is known for luxury skincare and is an ideal partner for évolis® Professional.

WATCH: Cellmid gaining ground in USA and China following advances in Japan and Australia

Cellmid’s CEO Maria Halasz said: “Bloomingdales represents the third premium retail group in the USA for évolis® Professional.

"With our successful online business in Neiman Marcus, recent commencement of online sales via US based Soft Surroundings and now securing a partnership with Bloomingdales, our USA distribution strategy is clearly working.

“Overall, we are confident that our business focus to develop and market only clinically validated “first in class, best in class” consumer products will deliver growth for our shareholders.”

READ: Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

Bloomingdales is one of the oldest and most prestigious department stores in the US established in 1872 and currently owned by Macy’s, Inc (NYSE:M).

Bloomingdales will stock évolis® Professional in its retail stores and online channels.

Sales are expected to commence in the upcoming September quarter.

READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

Cellmid’s consumer health subsidiary Advangen generates all of the company’s revenue.

The consumer health segment sells hair growth products such as évolis® in Australia, Japan and the US, which were developed using FGF5 related intellectual property.

]]>
Tue, 24 Apr 2018 10:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195611/cellmid-secures-partnership-with-bloomingdales-to-sell-volis-195611.html
<![CDATA[News - Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected ]]> https://www.proactiveinvestors.com.au/companies/news/195517/cellmid-s-year-to-date-sales-exceed-full-year-sales-for-2017-with-further-momentum-expected-195517.html Cellmid Limited (ASX:CDY) has reported a record quarter of receipts of $2.2 million in the three months ending March 31, 2018.

Strong December sales where revenues were recognised in the latest quarter served to support the company’s cash on hand position of $3.4 million as at the end of March.

This represented an 81% increase compared with the prior comparable period, as several new initiatives by the life sciences group began to gain traction.

Advangen boosts sales

The strong December sales performance in the consumer health division could largely be attributed to sales of Advangen products.

These sales were achieved via Japanese-based television shopping channel, QVC.

The Japanese subsidiary continues to be cash flow positive.

WATCH NOW: Cellmid gaining ground in USA and China following advances in Japan and Australia

Consumer health revenues for fiscal 2018 to date have reached $4.49 million, exceeding total sales for fiscal 2017 of $4.45 million.

Management highlighted that this is a strong indication of the expected sales growth in fiscal 2018 with the added impact of US e-commerce sales, launched in September 2017.

The company should also benefit from its near-term entry into China.

Cellmid forecasts sustained growth

Management said Cellmid was well placed to deliver revenue growth in fiscal 2018, particularly given year-to-date sales have already exceeded last year’s total sales.

Planned marketing and distribution initiatives scheduled to occur prior to fiscal year-end should provide additional momentum.

New revenue streams from the company’s distribution channel strategy and the launch of new products are expected to drive additional growth into fiscal 2019.

]]>
Mon, 23 Apr 2018 11:51:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195517/cellmid-s-year-to-date-sales-exceed-full-year-sales-for-2017-with-further-momentum-expected-195517.html
<![CDATA[Media files - Cellmid gaining ground in USA and China following advances in Japan and Australia ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9055/cellmid-gaining-ground-in-usa-and-china-following-advances-in-japan-and-australia-9055.html Thu, 12 Apr 2018 12:47:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9055/cellmid-gaining-ground-in-usa-and-china-following-advances-in-japan-and-australia-9055.html <![CDATA[News - Cellmid convening global meeting of midkine researchers in Germany ]]> https://www.proactiveinvestors.com.au/companies/news/194469/cellmid-convening-global-meeting-of-midkine-researchers-in-germany-194469.html Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.

The symposium will be a global meeting of key opinion leaders, clinicians and research scientists involved in midkine (MK) research.

READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product

The event follows on the success of the previous four scientific meetings on midkine held in Sydney (2010), Istanbul (2012), Kyoto (2014) and Budapest (2016).

Assessing midkine antibodies in chronic heart failure

Midkine is a promising molecule in drug development. It is a heparin-binding growth factor that promotes cell growth, survival, differentiation and cell migration.

It is almost undetectable in healthy adults, however, is upregulated as part of the pathogenesis (development) of certain chronic diseases.

Munich has been chosen for the symposium as it is the home Ludwig Maximilian University (LMU), where researchers are currently assessing Cellmid’s midkine antibodies in a model of chronic heart failure.

READ: Cellmid enters exclusive distribution agreement for anti-ageing skincare product

The research at LMU is the subject of a recently filed patent application by Cellmid and is expected to deliver vital data and add to the company’s already substantial midkine asset portfolio.

Promoting interactions between midkine researchers

The symposium will host delegates from twelve countries with expertise in various therapeutic and diagnostic fields and will enhance interactions between leading researchers within the midkine community.

Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid’s therapeutic programs including the recently completed clinical studies carried out at the University of Gothenburg, Sweden.

The study in Sweden demonstrated that midkine is associated with prostate cancer progression and treatment resistance.

Symposium to be led by Dr Ludwig Weckbach

The symposium will be hosted by the team led by clinician scientist Dr Ludwig Weckbach, Cellmid’s research partner based at the Biomedical Center and Department of Cardiology, LMU.

Dr Weckbach will be welcoming symposium delegates as well presenting his group’s innovative discoveries demonstrating the clinical potential of therapeutic antibodies targeting midkine for chronic heart failure.

]]>
Mon, 09 Apr 2018 11:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194469/cellmid-convening-global-meeting-of-midkine-researchers-in-germany-194469.html
<![CDATA[News - Cellmid strengthens its position in hair and skin care market with leading anti-ageing product ]]> https://www.proactiveinvestors.com.au/companies/news/194207/cellmid-strengthens-its-position-in-hair-and-skin-care-market-with-leading-anti-ageing-product-194207.html Cellmid Limited (ASX:CDY) is one of the more diversified ASX-listed biopharmaceutical groups with prominent products in the health and well-being sectors as well as traditional clinical markets.

Recent developments in relation to its foray into anti-ageing skincare products are likely to bring its broader range of health, skin and hair care products under the microscope.

While the company has a strong portfolio of clinical products at various stages, some of which are generating revenue streams, Proactive Investors focuses on the health and well-being side of its business in this report.

A household name in evolis® leads the way

One of the company’s best-known consumer lines is its evolis® range of hair care products.

Manufacture of the evolis® Professional range was completed in June 2017, which allowed the company to sign its first retail partnership with Neiman Marcus.

This is only the beginning of the group’s US market approach with retailers and management expects to secure a number of similar relationships in North America.

Strong sales growth in Japan and Australia

Japan has also been an important market for the company with sales increasing by 39% in fiscal 2017 to about $3 million.

In Australia, consumer health sales increased 81% to reach nearly $1.5 million in fiscal 2017.

While the pharmacy segment remained the most significant channel, website sales have also increased significantly.

Management has responded to this trend by establishing a dedicated digital marketing team which it anticipates will grow sales in the e-commerce channel.

Concept store being established in Japan

Such is the strength of the company’s product acceptance in Japan that management has established its first concept store in Ginza, one of Tokyo’s premium shopping districts.

The launch of the Advangen Hair Biology store is expected in the second half of 2017.

Initially stocked with the Japanese products, especially Jo-Ju®, the store will take advantage of the brand awareness built through two years of television shopping channel presence.

The global évolis® Professional branded shampoos, conditioner and activators are expected to become available in the concept store in late 2018.

Advangen continues to be a strong revenue driver

Since the acquisition of Advangen Inc some five years ago the company has generated strong revenue growth.

Sales of the consumer health products increased almost four-fold in four years and management is looking to this division to drive future earnings growth.

With new import permits now in place for Lexilis® and Jo-Ju®, Advangen commenced shipping again in FY2018, helping maintain the group’s strong revenue trajectory.

Anti-ageing hair care is fastest growing market

Anti-ageing hair care is the fastest growing segment in the hair care category and, predictably, competition is intensifying.

Advangen is leading the field with its first FGF5 inhibitor products range, a position that will be exploited to expeditiously achieve maximum market penetration.

The recognition of Advangen as a market leader in clinically validated topical hair loss treatments was further strengthened in 2017.

Publication of the first FGF5 inhibitor clinical study and more recently the company’s highly encouraging US consumer study have elevated the product’s profile even further.

Diversification into adjacent areas has been a strategic focus for Cellmid, and the distribution agreement just negotiated regarding the anti-ageing Fillerina® treatment is an important development.

Haircare and skincare come together

Cellmid has entered into an agreement with Labo International S.r.l regarding the exclusive distribution of Fillerina® in Australia and New Zealand for an initial period of up to five years.

The product is a market-leading Swiss anti-ageing skincare brand and management expects that it will be a robust profit driver, as well as being an ideal fit with Advangen.

It has been scientifically proven to reduce facial wrinkles, deliver measurable filling effects, increase facial volumes and decrease the clinical signs of skin ageing.

Fillerina® is the first non-invasive filler treatment with clinical study results published in a peer-reviewed article.

First in class, best in class

Management noted that it is a market leader in innovative, high-performance skincare within the fast-growing, anti-ageing cosmetics space globally.

Cellmid chief executive officer Maria Halasz said: “Our growth strategy for Advangen is focused on first in class, best in class, clinically validated anti-ageing products for hair, skin and body.

“Having built a successful distribution network for our FGF5 inhibitor hair products, Fillerina® is an exciting addition to our consumer health business.”

This is reflected in the record sales growth being achieved by the FGF5 product.

READ: Cellmid achieves record quarterly sales for its hair care products

Cellmid’s addressable market continues to experience exceptional growth.

Anti-ageing cosmetics market to grow 24% by 2021

The anti-ageing cosmetics market is experiencing strong growth, and according to Euromonitor 2017, it is predicted to expand a further 24% by 2021 in Australia.

Fillerina® is complementary to the company’s evolis® haircare range with its innovative, patented technology.

Importantly, the Fillerina® distribution agreement will generate efficiencies for Cellmid through increased utilisation of the company’s existing evolis® national sales and digital marketing team.

]]>
Wed, 04 Apr 2018 14:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194207/cellmid-strengthens-its-position-in-hair-and-skin-care-market-with-leading-anti-ageing-product-194207.html
<![CDATA[News - Cellmid enters exclusive distribution agreement for anti-ageing skincare product ]]> https://www.proactiveinvestors.com.au/companies/news/194199/cellmid-enters-exclusive-distribution-agreement-for-anti-ageing-skincare-product-194199.html Cellmid Limited (ASX:CDY) has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina® in Australia and New Zealand for an initial period of up to five years.

The product is a market leading Swiss anti-ageing skincare brand and management expects that it will make a strong contribution to profits.

Under the terms of the agreement, joint distribution and sales targets will be established and there will be a close marketing collaboration between the parties.

World first treatment process

Fillerina is a world-first, patented dermo-cosmetic filler treatment.

It has been scientifically proven to reduce facial wrinkles, deliver measurable filling effects, increase facial volumes and decrease the clinical signs of skin ageing.

Fillerina is the first non-invasive filler treatment with clinical study results published in a peer-reviewed article.

First in class, best in class

Management noted that it is a market leader in innovative, high-performance skincare within the fast-growing anti-ageing cosmetics space globally.

Cellmid’s chief executive officer Maria Halasz said: “Our growth strategy for the Advangen subsidiary is focused on first in class, best in class, clinically validated anti-ageing products for hair, skin and body.

“Having built a successful distribution network for our FGF5 inhibitor hair products, Fillerina is an exciting addition to our consumer health business.”

This is reflected in the record sales growth being achieved by the FGF5 product.

READ: Cellmid achieves record quarterly sales for its hair care products

Cellmid’s addressable market continues to experience exceptional growth.

Anti-ageing cosmetics market to grow 24% by 2021

The anti-ageing cosmetics market is experiencing strong growth and according to Euromonitor 2017, it is predicted to expand a further 24% by 2021 in Australia.

Fillerina is complementary to the company’s evolis® haircare range with its innovative, patented technology.

Importantly, the Fillerina distribution agreement will generate efficiencies for Cellmid through the increased utilisation of the company’s existing evolis national sales and digital marketing team.

Fillerina to benefit from established marketing division

The established marketing division already has an extensive presence throughout major retail channels such as pharmacies, as well as e-commerce distribution.

Labo Cosprophar AG is Cellmid’s parent company and its chief executive officer Marcel Leutzelschwab said: “We are excited to partner with Advangen for the exclusive distribution of our Fillerina product range in Australia and New Zealand.

“We believe that our product philosophy is perfectly aligned to maximise the market potential for Fillerina, which has become the leading dermo-cosmetic filler in more than 40 countries worldwide since its launch in 2013.” 

]]>
Wed, 04 Apr 2018 11:13:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194199/cellmid-enters-exclusive-distribution-agreement-for-anti-ageing-skincare-product-194199.html
<![CDATA[News - Cellmid appoints experienced retail executive to board as it targets US and Asia ]]> https://www.proactiveinvestors.com.au/companies/news/193743/cellmid-appoints-experienced-retail-executive-to-board-as-it-targets-us-and-asia-193743.html Cellmid Limited (ASX:CDY) has appointed Dennis Eck to the board as non-executive director.

A professional investor, Eck has 40 years’ senior management experience in the retail sector, leading the strategic direction of companies such as American Stores, Vons and ULTA in the US.

He has also been engaged in a similar capacity with Coles Myer in Australia.

Relevant experience in cosmetics and hair care

Eck’s retail experience spans from fashion through to groceries and includes cosmetics and hair salons.

As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses, delivering outstanding shareholder returns.

Cellmid chairman David King said: “We are delighted to welcome Dennis to the board and look forward to his continued valuable input regarding our product and distribution strategy for évolis.”

Important in entering US and Asian markets

With substantial US and Asian market opportunities for évolis®, Eck’s experience should be beneficial.

In December 2017, Eck made a strategic investment in Cellmid through a private placement by acquiring 2.7 million fully paid ordinary shares.

Consequently, his interests are closely aligned with the shareholders he represents. 

]]>
Mon, 26 Mar 2018 10:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193743/cellmid-appoints-experienced-retail-executive-to-board-as-it-targets-us-and-asia-193743.html
<![CDATA[News - Cellmid managing director and CEO buys shares on market ]]> https://www.proactiveinvestors.com.au/companies/news/190874/cellmid-managing-director-and-ceo-buys-shares-on-market-190874.html Cellmid Limited (ASX:CDY) has been shown support from its board and management as Maria Halasz, managing director and CEO, has increased her holding in the company.

Halasz purchased 70,000 shares through on-market trades to increase her total direct and indirect holding to over 1.38 million shares.

READ: Cellmid achieves record quarterly sales for its hair care products

The company finished the recent December quarter with $3.5 million in cash including $1.42 million in receipts from customers.

]]>
Wed, 31 Jan 2018 14:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190874/cellmid-managing-director-and-ceo-buys-shares-on-market-190874.html
<![CDATA[News - Cellmid achieves record quarterly sales for its hair care products ]]> https://www.proactiveinvestors.com.au/companies/news/189771/cellmid-achieves-record-quarterly-sales-for-its-hair-care-products-189771.html Cellmid Limited’s (ASX:CDY) sales of its FGF5 inhibitor hair growth and anti-aging hair care products for Q2 FY2018 reached circa $2 million, more than double the sales from the same period last year.

The company’s consumer health subsidiary Advangen sells hair care products in Australia, Japan and the U.S.

Quarterly sales exceed $2 million for the first time

This is the first time that Cellmid has recorded sales above $2 million for the quarter, having achieved a 34% increase on the highest previous quarterly result of $1.5 million.

The substantial increase in sales was the result of continued success with television shopping channel QVC in Japan.

Cellmid’s ‘million-dollar day’ sale on 21 December 2017 on the QVC television shopping channel in Japan has been a remarkable success.

The company also benefited from the commencement of shipping to China following the receipt of import permits for the Jo-Ju® and Lexilis® branded products.

READ: Cellmid makes move to sell hair loss products into China

The company had signed a master supply agreement with YPB Group Ltd (ASX:YPB) to market the company’s products in China.

This is part of a comprehensive strategy to enter the Chinese consumer health market with the company’s various brands of FGF5 inhibitor hair loss products.

READ: Cellmid ends the year on a high note after achieving quarterly targets

Cellmid has achieved key milestones and operational targets for the quarter ended 31 December 2017.

The company recently signed up with its second U.S. retail partner, Soft Surroundings.  Cellmid had successfully launched its product range on Neiman Marcus online earlier last year.

The évolis® Professional anti-aging hair care products were launched in Australian salons in November 2017. The roll-out, primarily through wholesale relationships, will continue in 2018.

Rare kidney disease studies progressing well

Cellmid’s ‘in live’ phase of the FSGS (a rare disease that attacks the kidney) studies at the Westmead Institute in Sydney was completed in December 2017.

The tissue and blood data are currently being analysed with an early indication that one of the company’s antibodies, not previously tested, is showing efficacy in this model.

]]>
Wed, 10 Jan 2018 15:01:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189771/cellmid-achieves-record-quarterly-sales-for-its-hair-care-products-189771.html
<![CDATA[News - Cellmid ends the year on a high note after achieving quarterly targets ]]> https://www.proactiveinvestors.com.au/companies/news/189697/cellmid-ends-the-year-on-a-high-note-after-achieving-quarterly-targets-189697.html Cellmid Limited (ASX:CDY) has achieved key milestones and operational targets for the quarter ended 31 December 2017.

The company’s consumer health subsidiary Advangen sells hair growth products in Australia, Japan and the U.S. and currently generates all of Cellmid’s revenue.

Significantly, Cellmid’s ‘million-dollar day’ sale on 21 December 2017 on the QVC television shopping channel in Japan has been an outstanding success.

Advangen concept store launched in Japan

The store launch in October 2017 was a well-attended public relations event, followed by several articles on Advangen’s technology and products in local publications.

Located in Tokyo’s prestigious Ginza Core shopping centre, the retail store provides hair analysis services in addition to selling products, and is co-promoted with the QVC shopping channel.

Further retail expansion in the U.S.

The company recently signed up with its second U.S. retail partner, Soft Surroundings.  Cellmid had successfully launched its product range on Neiman Marcus online earlier last year.

There will be an online launch initially for Soft Surroundings in a similar path to Neiman Marcus since established retailers require new brands to perform online before they commit to store launches.

The évolis® Professional range launched in Australian salons

The évolis® Professional anti-aging hair care products were launched in Australian salons in November 2017.

The roll-out, primarily through wholesale relationships, will continue in 2018.

Cellmid will engage a small sales force in 2018 to optimise return on investment in this channel, as sales are expected to increase gradually.

Kidney disease studies in Australia progressing well

The ‘in live’ phase of the FSGS (a rare disease that attacks the kidney) studies at the Westmead Institute in Sydney was completed in December 2017.

The tissue and blood data are currently being analysed by Cellmid.

Importantly, there is an early indication that one of the company’s antibodies, not previously tested, is showing efficacy in this model.

READ: Cellmid receives funding from strategic U.S. investor

The company recently received $1 million in the form of a strategic investment from U.S. based investor, Dennis Eck.

Eck is a professional investor with 40 years’ senior management experience in the retail sector including beauty.

]]>
Tue, 09 Jan 2018 15:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189697/cellmid-ends-the-year-on-a-high-note-after-achieving-quarterly-targets-189697.html
<![CDATA[News - Cellmid receives funding from US strategic investor ]]> https://www.proactiveinvestors.com.au/companies/news/188905/cellmid-receives-funding-from-us-strategic-investor-188905.html Cellmid Limited (ASX:CDY) has received $1 million in the form of a strategic investment from US based investor, Dennis Eck.

Notably, the shares to be placed with Eck are priced at $0.38, representing no discount to the last Thursday's closing price.

Eck is a professional investor with 40 years’ senior management experience in the retail sector including beauty.

Cellmid board to utilise new investor’s retail experience

Eck will be advising Cellmid’s board on its US retail strategy in 2018.

The company continues to progress its strategy to access the premium retail market for its evolis® branded FGF5 inhibitor hair loss products.

Maria Halasz, chief executive, said: “It is very exciting to secure support from a strategic investor of Dennis Eck’s industry experience and wisdom.

“We are looking forward benefiting from his insights into retail."

The expansion of evolis® anti-aging hair care products

In July 2016 Cellmid embarked on a US market strategy for its evolis® branded hair loss and anti-aging hair care products.

Since then, Cellmid has developed the evolis® Professional branded anti-aging hair care products.

It has successfully completed manufacture of the range and secured prestige retail distribution with Neiman Marcus and Soft Surroundings in the US.

READ: Cellmid secures second US partner to sell évolis hair growth products

Cellmid recently secured its second premium retail partner in the US, Soft Surroundings.

Soft Surroundings owns 59 stores across the US and will sell Cellmid’s évolis® Professional product range.

]]>
Mon, 18 Dec 2017 08:55:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188905/cellmid-receives-funding-from-us-strategic-investor-188905.html
<![CDATA[News - Cellmid secures second US partner to sell évolis hair growth products ]]> https://www.proactiveinvestors.com.au/companies/news/188399/cellmid-secures-second-us-partner-to-sell-volis-hair-growth-products-188399.html Cellmid Limited (ASX:CDY) has secured its second premium retail partner in the US, Soft Surroundings.

Soft Surroundings owns 59 stores across the US and will sell Cellmid’s évolis® Professional product range.

Soft Surroundings also has a strong online presence

Headquartered in St. Louis, Soft Surroundings is a lifestyle brand and retailer of women’s beauty products, home and apparel with a fast-growing e-commerce platform.

Soft Surroundings positions itself as a luxury lifestyle brand for busy women of all ages.

Maria Halasz, chief executive, said: “Soft Surroundings has grown remarkably during a challenging period for retailers due to impeccable customer service.

“We look forward to building a strong relationship with their customer base in 2018 and beyond.”

READ: Cellmid makes move to sell hair loss products into China

The agreement is the second premium retail relationship for Cellmid’s évolis® Professional product range, after signing the agreement with Neiman Marcus in August 2017.

It is a key milestone in the company’s US distribution strategy.

Targeting the $14.7 billion prestige hair market

Cellmid’s consumer health subsidiary Advangen currently generates all of the company’s revenue.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

Cellmid is targeting the prestige hair care market, which is expected to reach global sales of $14.7 billion annually by 2021.

]]>
Thu, 07 Dec 2017 10:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188399/cellmid-secures-second-us-partner-to-sell-volis-hair-growth-products-188399.html
<![CDATA[News - Cellmid share consolidation will reflect growing value of assets ]]> https://www.proactiveinvestors.com.au/companies/news/188235/cellmid-share-consolidation-will-reflect-growing-value-of-assets-188235.html Cellmid Limited (ASX:CDY) has completed a 20:1 consolidation of its securities.

The company believes the consolidation will ensure the growing value of its assets is properly reflected in its share price over time.

The life sciences company now has almost 53.5 million ordinary shares and 1.65 million unlisted options.

Revenue in Cellmid’s consumer health division has quadrupled since 2014.

READ: Cellmid's directors show vote of confidence with on-market buying spree

Dr David King, chairman, said: “The consolidation is an essential next step on the path to secure the long-term success of Cellmid and it is expected to benefit all shareholders.”

Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment sells hair growth products in Australia, Japan and the U.S., which were developed using FGF5 related intellectual property.

READ: Cellmid makes move to sell hair loss products into China

It also recently signed a master supply agreement with YPB Group Ltd (ASX:YPB) to market évolis hair growth products in China.

During the recent September quarter, the consumer health segment achieved sales of $1.03 million, up 4% on the prior corresponding quarter.

The consolidation was approved by shareholders on 23 November 2017.

]]>
Tue, 05 Dec 2017 12:48:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188235/cellmid-share-consolidation-will-reflect-growing-value-of-assets-188235.html
<![CDATA[News - Cellmid makes move to sell hair loss products into China ]]> https://www.proactiveinvestors.com.au/companies/news/187905/cellmid-makes-move-to-sell-hair-loss-products-into-china-187905.html Cellmid Limited (ASX:CDY) has signed a master supply agreement with YPB Group Ltd (ASX:YPB) to market the company’s évolis hair loss products in China.

The agreement will see Cellmid utilise YPB’s CONNECT platform, which will help Cellmid connect with its Chinese customers.

This is part of a comprehensive strategy to enter the Chinese consumer health market with the company’s various brands of FGF5 inhibitor hair loss products.

READ: Cellmid's directors show vote of confidence with on-market buying spree

YPB will supply Cellmid with QR labels to be applied to its products for two key reasons.

Firstly, it protects Cellmid’s product against counterfeits and fakes as consumers are able to use their mobile phone to scan the QR code to verify the product authenticity.

Secondly, the QR code becomes a point for data collection and communication with Cellmid’s Chinese customer base.

Gaining an in-depth knowledge of the customer

Mobile device scanning of the QR code launches a cascade of digital events that sees CONNECT capture and analyse data.

This data provides Cellmid with deep knowledge of its consumers and the capacity to develop personalised interactions with them.

Once that connection is established, CONNECT can then be used for a range of personalised education, marketing and promotional activities to enrich experiences and increase loyalty.

Chief executive expects return on investment

Maria Halasz, chief executive, said: “Access to the CONNECT platform is expected to be transformative for our consumer strategy in China.

“Knowing the customer behind each sale means that we can become partners in their hair health and provide tailored, personalised information and products to suit their individual needs.

“Together with our multilayered strategy to access the Chinese consumer market, the CONNECT platform is expected to improve our return on marketing investment significantly.”

September quarter sales reach $1.03 million

Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

The majority of sales are generated in Japan and Cellmid also recently launched its lead revenue driving évolis hair loss products into the U.S. market.

]]>
Tue, 28 Nov 2017 17:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187905/cellmid-makes-move-to-sell-hair-loss-products-into-china-187905.html
<![CDATA[News - Cellmid's directors show vote of confidence with on-market buying spree ]]> https://www.proactiveinvestors.com.au/companies/news/186700/cellmid-s-directors-show-vote-of-confidence-with-on-market-buying-spree-186700.html Cellmid Ltd (ASX:CDY) has been busy this week showcasing the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.

The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society.

READ NOW: Cellmid steps onto world stage for hair research in Japan.

Cellmid has also just opened its first Advangen Hair Biology concept store in Tokyo.

The directors of the company are putting their own money behind the company's strategy, adding a vote of confidence in operations by buying shares on-market.

Dr David King, chairman, made a direct interest purchase of 4 million shares for $80,000, and he also holds an indirect stake of 24 million shares and a line of 4 million unlisted options.

Maria Halasz, managing director and chief executive officer, snapped up 2 million shares on-market for just over $41,000, increasing her direct stake to 6 million shares along with 12 million loan shares.

Halasz has an additional an indirect position of circa 13 million.

Dr Edward Fintan Walton, a non-executive director, picked up 500,000 shares for $11,000, increasing his direct stake to 1.3 million shares and 2 million unlisted options.

Finally, Dr Martin Cross was recently appointed to the board as a non-executive director, also purchased an indirect stake (Anna Cross) in the company buying 900,000 shares for $19,800.

]]>
Fri, 03 Nov 2017 12:54:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186700/cellmid-s-directors-show-vote-of-confidence-with-on-market-buying-spree-186700.html
<![CDATA[News - Cellmid's newly appointed director Dr Martin Cross lifts indirect stake on-market ]]> https://www.proactiveinvestors.com.au/companies/news/186526/cellmid-s-newly-appointed-director-dr-martin-cross-lifts-indirect-stake-on-market-186526.html Cellmid Ltd (ASX:CDY) just last month appointed the experienced Dr Martin Cross as a non-executive director, a highly regarded pharmaceutical executive with over 30 years’ experience.

READ NOW: Cellmid makes key appointment to the board

In a vote of confidence, Dr Cross has now revealed an increase in indirect holdings (Anna Cross) in the company, with a purchase of 900,000 shares on market for a consideration of $19,800.

Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

Cellmid will be presenting this week at the World Congress for Hair Research in Kyoto, Japan.

READ NOW: Cellmid steps onto world stage for hair research in Japan ]]>
Wed, 01 Nov 2017 10:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186526/cellmid-s-newly-appointed-director-dr-martin-cross-lifts-indirect-stake-on-market-186526.html
<![CDATA[News - Cellmid steps onto world stage for hair research in Japan ]]> https://www.proactiveinvestors.com.au/companies/news/186519/cellmid-steps-onto-world-stage-for-hair-research-in-japan-186519.html Cellmid (ASX:CDY) will be presenting the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.

Dr Dominic Burg will be presenting the results of the recently published clinical study describing the efficacy of the FGF5 inhibiting évolis® tonic formulation.

The talk will be given on the first day and in front of the entire congress, making it one of the most significant presentations during the three days of proceedings.

Key findings of the recently published clinical study demonstrated that topical use of évolis® was effective against hair loss in men and women.

Over 16 weeks of treatment évolis®:

- Reduced hair loss by 82%;
- Increased the rate of actively growing hair follicles by 44%; and
- Improved hair density.

World Congress for Hair Research

The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society.

The congress is attended by more than 700 hair biologists, dermatologists, cosmetic scientists and hair transplantation surgeons from over 50 countries.

The presentation of results on the use of Advangen’s FGF5 inhibiting topical formulation to such an internationally recognised expert audience will provide an excellent avenue for exposure of the company’s technology, compelling clinical data and products.

A second abstract on the Cellmid’s FGF5 technology will be presented in the form of a scientific poster, a common occurrence at the conference.

Background

Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

The majority of sales are generated in Japan and Cellmid most recently launched its lead revenue driving évolis® hair loss products into the U.S. market.

Cellmid finished the September quarter with circa $2.9 million in cash, which didn’t include the $0.95 million tax credit received in early October.

The company recently opened its first Advangen Hair Biology concept store in Tokyo, Japan.

READ NOW: Cellmid lifts revenue options after taking clinically validated hair products to Tokyo ]]>
Wed, 01 Nov 2017 08:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186519/cellmid-steps-onto-world-stage-for-hair-research-in-japan-186519.html
<![CDATA[News - Cellmid lifts revenue options after taking clinically validated hair products to Tokyo ]]> https://www.proactiveinvestors.com.au/companies/news/186233/cellmid-lifts-revenue-options-after-taking-clinically-validated-hair-products-to-tokyo-186233.html Cellmid Ltd (ASX:CDY) continues its global roll-out and has now opened its first Advangen Hair Biology concept store in Tokyo, Japan.

The store, named after wholly owned consumer health subsidiary Advangen, is located in Ginza, the most prestigious and busiest shopping district in Tokyo, in the well-established Ginza Core building.

Koichiro Koike, managing director for Advangen Japan, commented:

"Advangen Hair Biology is the first specialist store solely focused on solving hair challenges with clinically validated and naturally based products.

"We hope to emulate the success of other specialist brands such as Jurlique and L’Occitane that grew rapidly on similar consumer trends."

Initially selling Advangen’s Japanese FGF5 inhibitors, including the Jo-Ju® and Lexilis® brands, the Hair Biology concept store is expected to build on the success of the JoJu® products that have been sold on the QVC television shopping channel since 2015.

This provides another opportunity for Cellmid to grow its revenues, as it has been doing with hair care products in the U.S.

Target market in Japan

Targeting the 40% of women and 50% of men over 40 with various hair loss concerns, the concept store will be advertised on QVC.

Customers will be invited to the store at the end of each Advangen shopping segment to receive a hair assessment and experience the FGF5 inhibitor products.

Specialist cosmetics retailers have been growing rapidly against the trend of otherwise contracting generalist retail.

ULTA, one of the largest cosmetics retailers in the U.S., is expected to add 100 new stores in 2018 to their existing portfolio of around 1,000 retail outlets.

Sephora, the largest specialist retailer of cosmetics operates 2,300 stores in 33 countries and it is expanding rapidly in established and emerging markets.

Both of these groups have been leaders in experiential marketing, allowing for an interactive shopping experience that is not possible through online purchase.

Their success demonstrates that customers of all ages demand to try the products before they buy in this category.

Advangen’s Hair Biology concept store is tapping into this trend with opening an experiential, consultative space for customers.

Unlike in generalist retail, customers can get a hair analysis service, followed by personalised product recommendations to solve their specific hair challenges.

READ NOW: Cellmid to benefit from share consolidation as revenues grow ]]>
Thu, 26 Oct 2017 13:46:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186233/cellmid-lifts-revenue-options-after-taking-clinically-validated-hair-products-to-tokyo-186233.html
<![CDATA[News - Cellmid to benefit from share consolidation as revenues grow ]]> https://www.proactiveinvestors.com.au/companies/news/186066/cellmid-to-benefit-from-share-consolidation-as-revenues-grow-186066.html Cellmid Ltd (ASX:CDY) is proposing a consolidation of its securities at the ratio of 20 to 1 during the upcoming Annual General Meeting.

The consolidation with reduce share price volatility and reduce administration costs.

It will also attract a broader range of investors, as many are reluctant to invest in lower priced shares and often have investment restrictions to invest in such companies.

Dr David King, chairman, commented:

"The proposed 20:1 consolidation is an essential next step on the path to secure the long-term success of Cellmid and it is expected to benefit all shareholders."

Attracting partners

In 2016, the board developed a series of strategic initiatives, with the midkine and consumer health businesses being separated into their wholly-owned operational entities, Lyramid, Kinera and Advangen. 

The benefits of this operational split have already started to show as partnering and funding discussions are in progress for the standalone businesses.

Therefore, potential partners for the company's drug development are not distracted by the consumer health business, and vice versa.

READ NOW: Cellmid delivers positive results using the evolis® Professional product range ]]>
Tue, 24 Oct 2017 12:47:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186066/cellmid-to-benefit-from-share-consolidation-as-revenues-grow-186066.html
<![CDATA[News - Cellmid makes key appointment to the board ]]> https://www.proactiveinvestors.com.au/companies/news/185600/cellmid-makes-key-appointment-to-the-board-185600.html Cellmid Ltd (ASX:CDY) has appointed Dr Martin Cross as a non-executive director, effective immediately.

Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles in global business development, marketing, sales, product development and management roles.

From 2010 to 2013, Dr Cross was the managing director of Alphapharm, the largest generics company in Australia, with responsibility for 750 employees and sales of over US$500 million per annum.

During the same period, he was chairman of both the Generics Medicine Industry Association and the Pharmaceutical Industry Council.

Dr David King, chairman, commented: "We are delighted to welcome Martin onto the board as non-executive director.

"His broad experience in the global pharmaceutical industry and understanding of the consumer health space will be invaluable in both our midkine and Advangen businesses."

Cellmid develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

]]>
Mon, 16 Oct 2017 10:54:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185600/cellmid-makes-key-appointment-to-the-board-185600.html
<![CDATA[News - Cellmid's Maria Halasz discussed growing revenue streams at Proactive's CEO Sessions ]]> https://www.proactiveinvestors.com.au/companies/news/185142/cellmid-s-maria-halasz-discussed-growing-revenue-streams-at-proactive-s-ceo-sessions-185142.html Cellmid's (ASX:CDY) chief executive, Maria Halasz, joined Proactive's CEO Sessions in Sydney on Tuesday 3rd October and Melbourne on Tuesday 4th October.

The company is growing revenues from sales of its hair care products in the U.S.

50% discount on all evolis products. The code Proinvestovs50 will be valid until 13th October 2017.

To claim the discount, put the code in at checkout and the payment amount will automatically be adjusted to 50%.

Please note this code will work on the www.evolisprofessional.com.au and www.evolisproducts.com.au websites for 1 week only.

ACCESS THE FULL PRESENTATION HERE


 

]]>
Fri, 06 Oct 2017 12:48:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185142/cellmid-s-maria-halasz-discussed-growing-revenue-streams-at-proactive-s-ceo-sessions-185142.html
<![CDATA[News - Cellmid gets tax incentive for melanoma, hair growth research programs ]]> https://www.proactiveinvestors.com.au/companies/news/184946/cellmid-gets-tax-incentive-for-melanoma-hair-growth-research-programs-184946.html Cellmid Limited (ASX:CDY) has received $947,000 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2017 financial year.

The tax credit relates to research and development expenditure incurred by Cellmid in relation to its midkine and FGF5 inhibitor programs.

Cellmid’s midkine technology recently received scientific endorsement with a publication in the scientific journal Nature, confirming midkine’s crucial role in the metastasis of aggressive melanoma.

The company’s pre-clinical validation programs for midkine are also continuing in animal models of chronic kidney disease and systemic complications.

Cellmid’s novel FGF5 inhibitor hair growth products are sold as over-the-counter, non-prescription natural medicines and cosmetics.

The company recently completed the first consumer experience study using the FGF5 inhibitor based evolis® Professional product range.

Significantly, 98% of consumers recorded new hair growth and 97% reported decreased hair fall by using évolis® over 120 days.

The consumer study results are critical for the company’s U.S. premium retail strategy, and the data will be the key resource for the underlying marketing and public relations activities.

Cellmid is continuing to grow revenues from its consumer health division, through the wholly-owned subsidiary Advangen, which sells hair growth products.

Find out more from Maria Halasz at Proactive's CEO Sessions.

Click below to register

- Melbourne: Wednesday 4th October.
 

]]>
Tue, 03 Oct 2017 11:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/184946/cellmid-gets-tax-incentive-for-melanoma-hair-growth-research-programs-184946.html